The Nicotine Landscape in 2030: A Mid-Decade Progress Report

The year is 2026. The midpoint of the decade is approaching. The nicotine landscape has been transformed in the preceding decade—the rise of vaping, the JUUL epidemic, the EVALI crisis, the pouch explosion, the synthetic nicotine loophole, the PMTA process, the global divergence of regulatory frameworks. Looking ahead to 2030, what trajectories are likely, what uncertainties are most consequential, and what decisions made now will determine the landscape we inhabit at the end of the decade?

The combustible cigarette market will continue its global decline, but the decline will remain uneven. High-income countries with strong tobacco control and accessible alternatives will approach 'smoke-free' status. Several additional European countries will join Sweden below 5% smoking prevalence. The decline in LMICs will be slower, and absolute smoking numbers will continue to rise in sub-Saharan Africa and parts of Southeast Asia as population growth outpaces prevalence decline. The global smoking population will become increasingly concentrated in the world's poorest regions, widening the health equity gap. The cigarette industry will continue its dual strategy: promoting 'smoke-free' products in high-income markets while maintaining and expanding cigarette sales in LMICs.

The non-combustible nicotine market will continue to diversify and consolidate. Nicotine pouches will capture increasing market share, particularly among demographics (young adult males) that are abandoning both smoking and vaping. Vaping will stabilize as a mature product category, with innovation shifting from devices to formulations (improved nicotine delivery, reduced toxicant emissions). Heated tobacco will remain regionally significant (Japan, parts of Europe) but globally secondary to vaping and pouches. The market will be dominated by tobacco-owned companies, with independent manufacturers surviving only in niche segments and less-regulated markets. The consolidation of the reduced-risk market under tobacco-industry ownership will intensify the debate about whether the industry can be trusted to manage the transition away from cigarettes.

The regulatory landscape will remain fragmented but some convergence will occur. The evidence from the UK, Sweden, and New Zealand—countries that have implemented harm-reduction-oriented policies—will continue to accumulate, showing sustained smoking declines without the youth epidemics that critics predicted. This evidence will gradually shift the global discourse, but the institutional resistance to harm reduction—particularly in the WHO FCTC framework—will persist. By 2030, the U.S. regulatory framework will have evolved toward greater clarity: the PMTA process will have authorized a defined set of products, the enforcement gap will have narrowed (though not closed), and the nicotine-reduction standard for cigarettes will be either implemented or definitively blocked. The EU will have revised its Tobacco Products Directive, likely in a direction that's more accommodating of harm reduction, influenced by the UK's evidence and the practical impossibility of banning products that consumers access online and across borders.

The youth nicotine landscape will have shifted. The disposable vape epidemic will have peaked and declined, driven by a combination of regulation (bans, flavor restrictions), market saturation, and cultural change. Youth nicotine initiation will migrate toward oral products (pouches) and other discreet formats that are harder for parents and schools to detect. The overall youth nicotine use rate will likely be lower than its 2019 peak but higher than pre-vaping baselines—a 'new normal' where a significant minority of young people use nicotine in non-combustible forms. The public health significance of this 'new normal' will remain contested: the precautionary camp will view any youth nicotine use as a policy failure; the harm-reduction camp will note that youth smoking has continued to decline and that non-combustible nicotine use, while not benign, is dramatically less harmful than the cigarette smoking it replaced.

The LMIC dimension will become increasingly urgent as the decade progresses. The tobacco epidemic in Africa and South Asia will continue to mature. The healthcare systems in these regions—already overburdened with infectious disease and maternal-child health—will face a growing burden of tobacco-related non-communicable disease. The international community's investment in tobacco control in LMICs will remain inadequate relative to the scale of the epidemic. The tobacco industry will continue to exploit the regulatory gap, marketing cigarettes aggressively in populations with young demographics, weak regulation, and limited health literacy. By 2030, the global tobacco mortality will still be rising—the epidemic in LMICs will not yet have peaked. The progress made in high-income countries will be partially offset by the worsening epidemic in the countries least equipped to handle it.

The decisions made in the next four years—about regulatory frameworks, about harm-reduction integration into the FCTC, about investment in LMIC tobacco control, about honest risk communication—will determine whether 2030 represents a turning point in the global nicotine transition or a continuation of the current fragmented, inequitable trajectory. The tools to accelerate the end of the tobacco epidemic exist. The evidence supports them. The question is whether the political will to implement them will be summoned in the remaining years of the decade. The nicotine landscape in 2030 is not predetermined. It's being shaped by the choices being made right now.